Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has expanded its Phase III clinical trial, FLAMINGO-01, aimed at preventing breast cancer recurrences by initiating new study sites across major US cancer centers, including City of Hope in Los Angeles and Orange counties, Arizona, Atlanta, and Illinois. The trial evaluates GLSI-100, an immunotherapy that has received Fast Track designation. Dr. Hope S. Rugo, the principal investigator, continues her involvement in the study, which also includes her previous site at the University of California San Francisco.